Search Results

< Back to the supporters page ABOUT CRINETICS At Crinetics Pharmaceuticals, our singular focus is on transforming the lives of patients living with endocrinology-related conditions. Our goal is to discover, develop, and commercialize novel therapeutics that leverage our unique understanding of endocrinology and G-protein coupled receptors (GPCRs). Endocrinology impacts nearly every aspect of human health, and our passion for this work runs deep. Our novel molecules that have been purposefully designed by our world-class, in-house R&D team have the potential to lift the burden of disease across a wide range of endocrine diseases and endocrine-related tumors so that patients can focus on life. Learn about Crinetics work in Carcinoid Syndrome >> Learn more about Crinetics and our groundbreaking work here >> This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by the Neuroendocrine Cancer Foundation. Talk to your medical team about your individual care and treatment. Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

Find compassionate support and resources for navigating a recent neuroendocrine cancer diagnosis. You're not alone in this journey. Navigating Your Recent Neuroendocrine Cancer Diagnosis PARA ESPAÑOL, HAGA CLIC AQUI You’ve just been told that you have Neuroendocrine Tumor, Neuroendocrine Cancer, or Carcinoid. You may be feeling panic, disbelief, despair or even a sense of relief to finally have a correct diagnosis. After those initial waves subside and you are thinking clearly again, the biggest question on your mind may be – “now what?” One important thing you can do is to take control by becoming your own advocate and leading your health team. Here is a beginner’s guide to NET that provides helpful facts and tips. SEVEN FACTS ABOUT NET 1. Neuroendocrine cancer is also known as neuroendocrine tumor, or NET. 2. Neuroendocrine Cancer is uncommon. Eight in 100,000 people are diagnosed per year in the United States. 3. Neuroendocrine Cancer can affect neuroendocrine cells throughout the body. 4. Neuroendocrine Cancer may be difficult to diagnose. 5. Some (but not all) Neuroendocrine Cancer patients have symptoms from their cancer. 6. The cause of Neuroendocrine Cancer is unknown. 7. Seeking the opinion of a specialist is important for all neuroendocrine cancer patients. 1. Neuroendocrine Cancer is also known as Neuroendocrine Tumor, or NET. It is pronounced NOOR-oh-EN-doh-krin TOO-mer and often abbreviated as NET. Hear the pronunciation . There are many terms or acronyms you may hear. Here are some of them: Neuroendocrine Neoplasm (NEN) is the official medical term often seen in medical literature such as the World Health Organization (WHO) classification of NEN. NEN includes both NET and Neuroendocrine Carcinoma (NEC). More aggressive Neuroendocrine Carcinoma (NEC) is treated differently than Neuroendocrine Tumors. Well-Differentiated and Low or Moderate Grade (G1/G2) NET tends to be slow growing, compared to High Grade (G3) NET or NEC which tends to be faster growing and Poorly Differentiated. Carcinoid is an old term meaning “cancer-like” that is falling out of favor because it is not accurate. NET is not cancer-like; it is cancer. Though some are localized (meaning it has not spread from where it originated from), many are malignant (meaning it has spread from where it originated from). You may still hear some physicians refer to NETs that originate from outside the pancreas such as the lung or small intestine as carcinoid tumors. Neuroendocrine Cancer is often used to refer to NENs (NET or NEC) by patient advocacy organizations as it spreads awareness to the fact that NET is a type of cancer and not benign as previously thought. Other terms you might hear refer to the primary tumor site (e.g., PNET or pancreatic NET) or the hormone that the tumor secretes (e.g., Insulinoma or VIPoma). 2. NET is a rare cancer. About 8 in 100,000 people are diagnosed annually in the United States. NET is considered rare by incidence, the number of patients diagnosed per year in the U.S. The prevalence of patients living with NET exceeds those living with stomach and pancreatic adenocarcinoma combined. Both the incidence and prevalence of NET are on the rise. 3. NET can affect neuroendocrine cells throughout the body. These are hormone-producing cells, most commonly found in the gastrointestinal system (stomach, small intestine, large intestine, rectum), the lung, pancreas or other parts of the body. NET often spreads (or metastasizes) from the primary site of origin to the lymph nodes, liver and bones. The tumors that have spread are called metastases. A Note About Prognosis: A common question we hear is, “How long do I have to live?” It is common for patients to report that their doctor told them that they had only months to live with the recommendation to “get their affairs in order.” In contrast, NET specialists will often say, “We don’t know how long you have.” The more you learn about NET, the more you will learn that prognosis is difficult to predict. NET is unpredictable, and each person’s case is unique, so it is typically difficult to predict a prognosis. Also, many of the statistics you might read are outdated. There have been many recent advances in NET research, which have led to earlier detection and more treatment options. As a result, patients are living longer with the disease. There are many in the NET community living with this disease for over a decade. 4. NET is a cancer that is difficult to diagnose. This is because not everyone with NET is symptomatic. For those who do have symptoms (less than half of all NET patients), these symptoms are vague and include flushing, diarrhea, nausea, abdominal cramping, bloating/gas and shortness of breath. 5. Some (but not all) NET patients have symptoms from their cancer. Typically, only those patients who have hormone-producing tumors called functional tumors have symptoms. For example, about 20-30% of people with small bowel (NETs) develop Carcinoid Syndrome (CS) with tumors produce serotonin. 6. The cause is unknown. People often wonder if they might have done something to cause their cancer. The answer is NO. Although there are a few types of NET that have a genetic correlation, most have no known cause. 7. Seeking the opinion of a NET specialist is important for NET patients. When most people are first diagnosed with neuroendocrine cancer, it is usually not by a NET specialist. Most patients end up seeking a second opinion with a NET expert, which may mean traveling outside of the area in which they live. Because NET is a rare disease, many doctors know little about it or the recent advances in diagnosis and treatment. A NET specialist can help guide your treatment plan. They can collaborate with your multidisciplinary doctors to manage your symptoms, monitor your disease and recommend treatments best suited for you. According to a large-scale survey of NET patients , those who received their care at a NET specialty center felt significantly more satisfied with their medical treatment and more knowledgeable than those who did not visit a NET specialty center. 1. Get organized NET VITALS is an ideal place to start. NET VITALS is a downloadable document to collect and keep the essential information about your specific NET disease. This comprehensive, curated list, contains what you and your healthcare professionals need to know about your neuroendocrine cancer. NET VITALS is a patient-physician communication tool, a “passport,” containing all the vital NET information in one location and simple to bring to your medical appointments. While it is not a medical document, it has been reviewed by NET specialists who agree that completing NET VITALS, as much as possible before their appointment, is helpful. Please note: NET VITALS is intended for informational and educational purposes only. LACNETS does not collect or store your information. It is for your personal use only. NET VITALS Helps: Educate you on what information is crucial to know about your NET disease. You organize, collect and compile this information into one comprehensive document that is easy to share with all healthcare professionals. Prepare you to ask relevant questions of your NET specialist for an optimal visit. Record Keeping Tips: Many people choose a way to organize their information such as a three-ring notebook or file folder. If you keep paper copies of labs, imaging reports, and pathology reports, consider scanning them so you have a digital copy as well. This not only makes your records easier to access, it also ensures that you do not lose your only paper copy! Download the Abridge app to record your healthcare visits and get transcriptions you can reveiw. To obtain second opinions, choosing an electronic system of record keeping on your computer or a cloud service can be helpful if you want to send information electronically. Some people track lab results on a spreadsheet to follow trends. Whatever method you choose, organization is key! You want to know where everything is stored. Information should be easy for you to access and share with your medical team when needed. NET VITALS is an ideal place to keep your vital NET information. After every scan, go to medical records or the film library and ask for a CD of the scan images for your records. We recommend requesting two copies, one for your NET specialist and one for second opinions or other members of your medical team. Never give away your only copy of any CD, report or document. After any biopsy or surgery, ask your doctor for the pathology report. These are often unavailable in your online patient portal, so you may need to request a copy. After any surgery or procedure, ask for the operative report or procedure report. These are often unavailable in your online patient portal, so you may need to request a copy. 2. Educate yourself on the disease: Learn to speak "NET" Watch this short (~5min) “What is NET?”video . It is great to share with family & friends to help them learn and understand more about your cancer. Watch this helpful introduction to NETs presentation by NET expert Dr. Pamela Kunz, as well as the “NETs 101” presentation by Dr. Sandy D. Kotiah, Medical Oncologist at Mercy Medical. This informative presentation, “What to Expect with a NET Expert Consultation” by Dr. Heloisa Soares at Huntsman Cancer Institute. The LACNETS webinar, “Sequencing of Neuroendocrine Tumor Treatments” with Dr. Eric Liu, General Surgeon & Neuroendocrine Specialist at Rocky Mountain Cancer Center. Check out Triage Cancer’s valuable organization resources: “Checklist: Getting Organized.” “Checklist to Avoid Financial Toxicity ” Cancer Rights Guide: “Navigating Employment, Insurance, & Finances” The National Comprehensive Cancer Network (NCCN) is an alliance of the leading cancer centers across the country that develop and publish up-to-date, evidence-based practice guidelines called NCCN Guidelines . Because these NET guidelines are recognized as the standard in cancer care, it is an essential resource in discussions with your medical team. It is also an excellent reference when dealing with insurance claims. Order your free Neuroendocrine Cancer Guide for patients and families from Neuroendocrine Tumor Research Foundation (NETRF). Download or request The Healing NET Foundation Navigating the NET Patient Journey peer-to-peer publication for patients and caregivers. Canadian Neuroendocrine Tumor Society (CNETS) has a downloadable Reference Guide for Patients and Families. The Global NET Patient Information Pack by the International Neuroendocrine Cancer Alliance (INCA) is available for download in 10 languages. Connect with and learn from others who are living with or have been affected by NET. Register for our Weekly Virtual Support Group every Wednesday from 12-1:30 PM Pacific Time. Subscribe to the LACNETS YouTube channel to find over 275 videos on various topics. 3. Find Support Support groups are often a rich source of educational meeting and resources for patients and their families. People often learn much from the experiences of others. Some report finding their NET specialist(s) because of attending a support group. Join our support community . We often hear people say, "I thought I was the only one with the disease." Connecting with others can help you feel less alone. Connect with a mentor. NETCONNECT connects you with another NET patient or caregiver for questions, support and more. 4. Find a NET Specialist Studies show that NET patients who are seen by a multidisciplinary team tend to have better outcomes. Typically, NET centers are able to diagnose and treat NET faster and more accurately. It is best to have a multidisciplinary approach where a team of NET specialists with different areas of expertise get together and review your case. This often takes place at a tumor board where your case is discussed and reviewed by several doctors including medical oncologists, endocrinologists, gastroenterologists, surgeons, radiologists, nuclear medicine doctors, and pathologists. Since patients are not allowed to be present, this video of a mock tumor board at a LACNETS conference gives you an idea of what one is like. How to Find a NET Specialist: Neuroendocrine Tumor Research Foundation (NETRF) is a good place to start. Many of the NET specialists (including oncologists, surgeons, endocrinologists, etc.) have been speakers at past NET patient conferences and meetings. Find and watch NET experts from our Video Library . You may find it helpful to “see” the doctor before your appointment. 5. Decide who will be your quarterback Patients often see many doctors with different areas of expertise. Some patients seek opinions from multiple NET experts as well. The important thing is finding a physician who you feel listens to and addresses your concerns, explains things in a way you understand, and provides access to the treatments you need. A collaborative relationship is important, both with you and the rest of your team. Once you have selected your multidisciplinary medical team, decide who will lead and call the shots. 6. Attend a NET patient education conference Learn about upcoming virtual and in-person conferences hosted by LACNETS and the broader NET Community. It is worthwhile to stay connected and interact with NET experts, patients, caregivers and those who serve the NET Community. Click here to read "Why Attend NET Patient Education Conference" 7. Breathe And last but not least, don’t forget to breathe. Stop to reflect and remember the reason we educate ourselves is to LIVE better. For most of us, living with NET is more like running a marathon than a sprint. Some feel a pressure to spend every waking minute learning about the disease so they don’t miss something that could mean the difference between life or death. For the majority of NET patients, that is simply not reality. It is just as important to take care of our emotional, mental and spiritual health as it is our physical health. If you’re feeling overwhelmed, it’s a good idea to take a break and do something that is life-giving and unrelated to cancer. Find the presence of mind to enjoy life’s simple pleasures like a walk on the beach, being in nature, gardening, seeing a movie, going to a museum or attending a concert. When you feel rested and ready to resume your education, come back to learn more about NET. It’s amazing how restorative taking just one minute to breathe can be. Click here to read "Breathe" blog post SEVEN TIPS FOR THE NEWLY-DIAGNOSED PATIENT 1. Get organized 2. Educate yourself on the disease: Learn to speak "NET" 3. Find support 4. Find a NET specialist 5. Decide who will be your quarterback 6. Attend a NET patient education conference 7. Breathe

< Back to the supporters page Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

< Back to the supporters page ABOUT CURIUM "At Curium, we have a singular focus – to develop, manufacture and supply world-class radiopharmaceutical products around the globe. We strive to innovate further in nuclear diagnostics and therapies so we can enhance the lives of people with cancer." https://www.youtube.com/watch?v=nZrQMemmPBw Download the Detectnet™ Brochure >>> Download the Oncology Patient Education Brochure >>> Download the Nuclear Medicine Patient Education Brochure >>> CONTACT Jenny Yessaian RN, MBA Sr Director of Marketing C: +1.626.696.0535 111 Westport Plaza, Suite 800 St. Louis, MO 63146 This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by the Neuroendocrine Cancer Foundation. Talk to your medical team about your individual care and treatment. Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

< Back to the supporters page ABOUT NOVARTIS Novartis is reimagining cancer care with radioligand therapies (RLTs) for patients with advanced cancers, including neuroendocrine tumors. We are proud of our 30-year legacy as an innovator in the neuroendocrine tumor community, leading developments that strive to transform the lives of people with this rare disease. At Novartis, we have a commitment to working together with patients. Our significant investment in research and development underpins our commitment to using science-based innovation to address some of society's most challenging healthcare issues. Only by working together can we improve outcomes for patients and change the practice of medicine. For more information, please visit: https://us.lutathera.com . This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by NCF. Talk to your medical team about your individual care and treatment. Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

< Back to the supporters page Defeating cancer with radiopharmaceutical medicines Despite therapeutic advances made in the last decade, there remains a high unmet need for new cancer treatments. Radiation therapy is a proven approach to treating many cancers and is typically administered by an external beam of high energy rays. In contrast, radiopharmaceuticals selectively deliver radioisotopes to tumors via the bloodstream. Radiopharmaceuticals have the unique advantage of being both diagnostic and therapeutic. The same drug conjugate could be used for both diagnostic imaging and therapeutic use by switching out the radioisotope. Direct visualization of drug conjugate uptake by tumors with imaging allows for proper patient selection to receive the therapeutic radioisotope (e.g. Actinium-225). RayzeBio is sponsoring the phase 1/3 ACTION-1 study for patients who have inoperable, progressive, somatostatin receptor positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NET). The trial is a part of larger international study and will compare the standard of care therapy with 225Ac-DOTATATE (RYZ101). The phase 1 portion of the study will look at the safety and tolerability of RYZ101. The phase 1 of the study is currently enrolling at sites across the country. Main Eligibility Criteria: Over 18 years of age Grade 1-2 well differentiated GEP-NET (GI or pancreas) Ki67 <= 20% Progressive GEP-NET following 2 to 4 cycles of treatment with 177Lu-DOTATATE / 177Lu-DOTATOC. If 177Lu-DOTATATE or 177Lu-DOTATOC treatment was stopped before completing 4 cycles, it should not have been stopped early due to disease progression. Must have had some response to PRRT, defined as tumor shrinkage or tumor stability, that lasted at least 3 months following the last dose of prior 177Lu-DOTATATE/DOTATOC No prior treatment with alkylating agents No prior use of anticancer agents within the following intervals prior to the first dose of study drug: Peptide Receptor Radionuclide Therapy (PRRT): within <8 weeks Chemotherapy: within <6 weeks Small molecule inhibitors: within <4 weeks Biological agents: within <7 days or <5 half-lives No prior external radiation therapy, including stereotactic body radiation therapy (SBRT) No prior radioembolization treatment No significant cardiovascular disease No known brain metastases If you are interested in learning more, please ask your doctor to contact clinicaltrials@rayzebio.com . SITES CURRENTLY ENROLLING: Samuel Mehr, MD Nebraska Cancer Specialists Omaha, NE SMehr@NebraskaCancer.com Michael Morris, MD, MS Advanced Molecular Imaging and Therapy Glen Burnie, MD morrism@amit.health Daneng Li, MD City of Hope Duarte, CA danli@coh.org For more information, contact ClinicalTrials@rayzebio.com. This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by the Neuroendocrine Cancer Foundation. Talk to your medical team about your individual care and treatment. Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

< Back to the supporters page ABOUT IPSEN Ipsen is a global biopharmaceutical company focused on innovation and specialty care. At Ipsen, we develop and commercialize medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Disease. Our oncology work focuses on solid tumors and some of the hardest-to-treat cancers. We have a growing portfolio of therapies aimed at improving the lives of patients with gastrointestinal and pancreatic neuroendocrine tumors, carcinoid syndrome, and pancreatic cancer. Every day, our more than 5,700 employees worldwide, including over 600 in North America, work diligently to improve the lives of patients around the world. For more information please visit www.ipsenus.com . PATIENT BROCHURES Download the Patient Brochure Click here to download the injection prep brochure OTHER RESOURCES Click here to download the SOMATULINE® DEPOTprescribing information packet. SOMATULINE® DEPOT Website IPSEN Cares Website Contact an Ipsen Representative Alice Donnelly Manager, Portfolio Communications Email: alice.donnelly@ipsen.com Phone: (973) 936-4697 This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by the Neuroendocrine Cancer Foundation. Talk to your medical team about your individual care and treatment. Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

< Back to the supporters page Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

< Back to the supporters page ABOUT TERSERA TerSera Therapeutics LLC acquires and develops specialty pharmaceutical products with a focus on select therapeutic areas. Our focus is to bring intelligent solutions to prescribers and patients who need better solutions. We deliver a comprehensive set of programs that go beyond the therapy itself in order to provide improved outcomes for patients. Our products make a difference for patients and provide solutions for prescribers. Learn more at www.tersera.com . Talk to a NET nurse about carcinoid syndrome diarrhea. Go to www.enrollxermelo.com . This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by the Neuroendocrine Cancer Foundation. Talk to your medical team about your individual care and treatment. Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

Join NCF for Neuroendocrine Cancer Day 2026. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page REGISTER DATE Sunday, November 8, 2026 8:30 AM - 3 PM LOCATION JW Marriott Las Vegas Resort & Spa 221 N Rampart Blvd Las Vegas, NV 89145 The 2026 NET Cancer Day Symposium will bring the neuroendocrine cancer community together in Las Vegas, Nevada, on Sunday, November 8th, for a day of education, connection, and awareness. Hosted by the Neuroendocrine Cancer Foundation, this in-person educational event is designed for patients, caregivers, families, and others seeking trusted, expert-led information about neuroendocrine cancer. ABOUT Hear presentations from neuroendocrine cancer experts and stories from those in the neuroendocrine cancer community. Learn about the latest in surgery, medical treatments, PRRT, symptom management, and clinical trials. Ask questions during the live question and answer sessions. Find out how you can spread awareness about neuroendocrine cancer. Kick-off reception with welcome breakfast. Lunch will be provided. This event is made possible by the generosity of donors and sponsors. AGENDA The full agenda and speaker list will be announced soon. Please check back closer to the event for the most accurate information. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 1: NUTRITION FOR NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE For our very first episode, we welcome NET Dietician Meghan Laszlo, MS, RD, CSO of Cedars-Sinai Medical Center. Meghan answers the top 10 NET nutrition questions, covering topics including carcinoid syndrome, prescription enzymes, diarrhea, recommended diet for NET patients, and much more! MEET MEGAN LASZLO Meghan Laszlo is a Registered Dietitian (R.D.) and a Board-Certified Specialist in Oncology Nutrition (C.S.O.) at Cedars Sinai’s Samuel Oschin Cancer Center. As an outpatient dietitian, she provides medical nutrition therapy to patients through nutrition counseling, education, and coordination of care. Meghan is fascinated by the nutritional aspects of gastrointestinal, neuroendocrine, and head and neck cancers and is dedicated to helping patients meet their individualized goals. In October 2019, Meghan gave a presentation for LACNETS titled "Nutrition for NETs." Watch the full video here >> TOP NET NUTRITION QUESTIONS 1. What kind of diet benefits NET patients? 2. Which foods cause carcinoid syndrome symptoms? 3. Which foods make diarrhea better and worse? 4. What kinds of fluids and how much are needed with diarrhea? 5. Which dietary supplements are beneficial for NET patients? 6. What is niacin and why is it important for individuals with carcinoid syndrome? 7. How does fat malabsorption effect digestion? 8. How do I know if the pancreatic enzymes are working? 9. What is small intestinal bacterial overgrowth (SIBO)? DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANKS TO OUR SPONSORS

Join NCF for California. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page Registration is closed. Please contact us at events@ncf.net to be added to the waitlist. ABOUT The Neuroendocrine Cancer Foundation is hosting an in-person Neuroendocrine Cancer Educational Event for patients and caregivers in Santa Monica, California on Saturday, May 17th, from 3:45 -7:30 PM. Hear four presentations from neuroendocrine cancer experts. Engage in two Q&A sessions. Listen to a patient story. Learn about liver-directed therapy, systemic therapy, PRRT, and clinical trials. Network with other patients and caregivers. A light dinner will be served. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. Special thanks to our host, Dr. Alexandra Gangi (Cedar-Sinai Medical Center). This event will not be broadcast or recorded. Note: The Neuroendocrine Cancer Foundation was formerly known as LACNETS. Read the full announcement here >>> LOCATION Sandbourne Santa Monica 1740 Ocean Avenue Santa Monica, CA 90401 THANKS TO OUR SUPPORTERS AGENDA Time Topic Speaker 3:45 - 4:15 PM Check-in 4:15 - 4:25 PM Welcome & Introductions Neuroendocrine Cancer Foundation Team 4:25 - 4:30 PM Patient Story 4:30 - 4:45 PM Liver-Directed Therapy: Understanding Minimally Invasive Options to Treat Liver Tumors Gabriel Lipshutz, MD, Interventional Radiologist, Cedars-Sinai 4:45 - 5 PM Systemic Therapy for NETs: Medical Options for Metastatic Tumors J. Randolph Hecht, MD, UCLA 5 - 5:45 PM Q&A with Expert Panel Callisia Clarke, MD, Julie Hallet, MD, Gabriel Lipshutz, MD, Randolph Hecht, MD; Moderated by Alexandra Gangi, MD 5:45 - 6:30 PM Break & Dinner 6:30 - 6:45 PM PRRT: Current & New Trends Thorvardur Halfdanarson, MD, Medical Oncologist, Mayo Clinic 6:45 - 7:00 PM Clinical Trials: The Latest & Greatest Heloisa Soares, MD, Huntsman Cancer Institute 7:00 - 7:30 PM Q&A with Expert Panel Thorvardur Halfdanarson, MD, Heloisa Soares, MD, Alexandra Gangi, MD; Moderated by Andrew Hendifar, MD 7:30 PM Closing Neuroendocrine Cancer Foundation Team This agenda is subject to change. Please check this page for the most updated agenda. ABOUT OUR SPEAKERS Callisia Clarke, MD, MS, FACS, FSSO Chief of MCW Surgery Medical College of Wisconsin Panelist Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Alexandra Gangi, MD Surgical Oncologist Cedars-Sinai Medical Center Moderator/Panelist Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. Thorvardur Halfdanarson, MD Medical Oncologist Mayo Clinic Speaker/Panelist Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson is the President Emeritus for the North American Neuroendocrine Tumor Society (NANETS). Julie Hallet, MD, MSc., FRCSC Surgical Oncologist Sunnybrook Health Sciences Center Panelist Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet’s research focuses on health services research to improve the fidelity of care delivery in cancer surgery through patient-centred quality monitoring, high-performing team care models, and patient risk-communication support. Her work has obtained over $10 millions in peer-reviewed operating grants and led to more than 220 peer-reviewed publications. J. Randolph Hecht, MD Medical Oncologist UCLA Health Speaker/Panelist Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. Andrew Hendifar, MD Medical Oncologist Cedars-Sinai Medical Center Moderator The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. J. Gabriel Lipshutz, MD Interventional Radiologist Cedars-Sinai Medical Center Speaker/Panelist H. Gabriel Lipshutz, MD is a board-certified, fellowship-trained vascular and interventional radiologist with the Cedars-Sinai S. Mark Taper Foundation Imaging Center. Dr. Lipshutz performs all peripheral endovascular and interventional procedures including embolizations and minimally invasive oncological treatments (chemoembolization, Y-90 radioembolization, RFA, cryoablation, microwave ablation, and irreversible electroporation (IRE). His responsibilities include consultation and treatment of outpatients and inpatients, including the evaluation of patients in the IR outpatient clinic. After earning his bachelor's degree from Wesleyan University, Dr. Lipshutz earned his medical degree from the University of California, San Francisco. He completed his internship in internal medicine at the University of Washington, his radiology residency at the Oregon Health and Sciences University, and his fellowship in interventional radiology at UCLA. Dr. Heloisa Soares Medical Oncologist Huntsman Cancer Institute Speaker/Panelist Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79.